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INTRODUCTION 
Endothelin-1 (ET-I), an endothelium-derived peptide, has a potent and sustained 
vasoconstrictor effect. ET-1 also has both positive inotropic and chronotropic effects 
on the heart2 and was reported to induce cardiac hypertrophy.3 The release of ET-1 
is increased during hypoxia and myocardial inkction leads to increased plasma levels 
of ET-1.4 Moreover, hypoxia increases the number of myocardial ET-1 binding sites5 
as well as a]-adrenergic receptors, the latter accompanied by an increase in phospho- 
lipase C (PLC) activity in response to receptor ~ t imula t ion .~ ,~  The signaling pathway 
activated by ET-1 also involves activation of PLC8,9 resulting in inositol 1,4,5-trisphos- 
phate (1(1,4,5)Pa)-induced Ca2+ mobilization and protein kinase C (PKC) activa- 
tion.10 Activation of PKC was shown to aggravate hypoxic myocardial injury presum- 
ably by stimulation of Na+/H+ exchange leading to Ca2+ overload by Na+/Ca2+ 
exchange.” Another acute effect of activation by ET-1 is enhanced CaZ+ entry 
through the T-type Ca2+ channels.I2 
The possibility that PLC activation, through increased ET-1 and receptor levels 
during hypoxia, leads to increased hypoxia-reoxygenation injury prompted us to inves- 
tigate the activity of PLC in cultured cardiomyocytes after ET-1 stimulation during nor- 
moxia and glucose-free hypoxia-reoxygenation. 
LZ This work was supported by Grant 89.221 from the Netherland Heart Foundation 
337 
338 ANNALS NEW YORK ACADEMY OF SCIENCES 
METHODS 
Primary cultures of neonatal ventricular myocytes were prepared from 1-2 day-old 
Wistar rats as described b e f ~ r e . ~  
Analysh of Waar-SOlubk Inositol Phosphates 
Cardiomyocytes, 4 days after plating, were labeled with 2 pCi myo-[2-3H]inositol/m1 
for 48 h. Before performing the experiments, myocytes were washed with incubation 
buffer (130 mM NaCI; 4.7 mM KCI; 1.3 mM CaC12; 0.44 mM NaH2P04; 1.1 mM 
MgS04; 20 mM NaHC03; 20 mM HEPES; pH 7.4, 37OC that was gassed with 
either 95% air/5% COz or 95% N2/5% CO2). Thereafter, cells were incubated as de- 
scribed in IABLES 1 and 2. Incubations were terminated by washing the cells followed 
by extraction with 4% perchloric acid and CHj0H:HCI (100: 1 vol/vol), respectively. 
Inositol phosphates (IPn) were quantified by chromatography on Dowex AG 1-X8 as 
described before.9 The total of cellular [3H]inositol was defined as the sum of water- 
soluble inositol-containing products together with inositol lipids. 
RESULTS AND DISCUSSION 
As previously shown9 exposure of cardiac myocytes to ET-1 (10-8 M) results in ac- 
tivation of PLC. Exposure of the cells to ET-1 for only 15 min led to persistent stim- 
ulation of IP, production, which declined to a low level after 4 h (IABLE l) ,  still 
above unstimulated cells. The decline was not caused by deterioration of cell viability 
as maximal stimulatability remained high over this period (TABLE 1). Not only was the 
TABLE 1. Long-Lasting but Desensitized Activation of PLC after Short (1 5 min) 
Exposure of Cardiomyocytes to ET-1 
Preincubation Incubation 
0-15 rnin 15-270 rnin 30-60 rnin 240-270 rnin 
Buffer ET- 1 25.6 f 6.9 34.9 f 0.2 
ET- 1 Buffer 13.0 f 3.8 2.6 f 0.3 
ET- 1 ET- 1 19.9 f 7.9 11.8 f 0.3 
Cardiomyocytes, prelabeled with myo-[2-3H]inositol, were preincubated with buffer or with 
ET-1 (10-8 M) for 15 min in the absence of Li+ followed by extensive washing of the cells. At 
different intervals after the onset ofthis initial incubation cells were challenged with LiCl(10 mM) 
in the absence or presence of ET-1 (10-8 M). Incubation in the presence of Li+ was always for 
30 min. After incubation, the cells were extracted and ['HIIPn was quantified. Further details 
are described in Materialr and Methd.  Results are mean f range/2 for two experiments. Note 
that the presented data are already corrected for unstimulated ['HIIPn levels (4.23 f 0.48). 
Addition During ['HIIPn Level 
(% of cellular [3H]inositol) 
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TABLE 2. Partial Inhibition of ET-1 Induced IPn Accumulation by Hypoxia but  
not by Reoxygenation 
PHIIPn Level (% of cellular 13Hlinositol) 
~ ~~ 
Basal ET-1 (10-8 M) Stimulated 
Normoxia Hypoxia Normoxia Hypoxia 
30 min 2.50 f 0.42 2.71 f 0.38 21.55 f 2.65 16.03 f 3.01 
60 min 2.59 f 0.38 2.85 f 0.30 21.58 f 3.95 13.06 f 2.91 
90 min 2.37 f 0.25 2.82 f 0.23 20.39 f 2.71 9.70 f 2.38" 
Reoxygenated 1.60 f 0.13 2.97 f 0.41"* 5.54 f 1.49 8.25 f 1.05 
Cardiomyocytes, prelabeled with mp[2-3H]inositol, were incubated in incubation buffer (see 
Mcthodr) at 37OC in 95% air/5% C02 (normoxia) or in 95% N2/5% C02 (hypoxia) for the peri- 
ods indicated in the table. Then ET-1 was added to 10-8 M in the presence of 10 mM LiCl and 
incubation proceeded under the same conditions for 15 min. For reoxygenation, hypoxic buffer 
was replaced with fresh normoxic buffer and the incubation was continued for 15 min whereafter 
ET-1 and LiCl were added as described above. To mimic the reoxygenation protocol, buffer ex- 
change was also performed after 90 rnin of normoxia. Further details are described in Methodr. 
Data are presented as mean f SEM, n Q 7-10, " p < 0.02 and *" p < 0.005 versus normoxia. 
ET-1 response desensitized but the responsiveness of cells to a second dose of ET-1 
was also diminished, remaining so up to 4 h.9 These results show that brief exposure 
of cardiomyocytes to ET-1 can lead to long-lasting but desensitized activation of PLC. 
To evaluate the ET-1-evoked IPn production during glucose-free hypoxia- 
reoxygenation, we established a model of cultured cardiomyocytes exposed to 95% 
&/!I% C02 for periods up to 90 min followed by 30-min reoxygenation by buffer- 
change in 95% air/5% C02. The severity of hypoxia-reoxygenation was characterized 
before by monitoring ATP depletion and lactate dehydrogenase (LDH) leakage during 
reoxygenation and these results (not shown) correlate nicely with earlier reports. 13.14 
Basal activity of PLC was not stimulated during 90-min hypoxia (TABLE 2). This con- 
trasts with earlier data15 where phosphatidylinositol (PI), PI(4)P and PI(4,5)P2 were 
decreased in mass suggesting PLC activation, but IPn was not measured. Stimulat- 
ability of the cardiornyocytes with ET-1 (lo+ M) stayed relatively constant during a 
90411  normoxic period (TABLE 2). However, after buffer change to mimic the reoxy- 
genation protocol, the ET-1 response was unexpectedly diminished. Hypoxia gradu- 
ally decreased the stimulatability of cardiomyocytes with ET-1 to 38% after 90 min. 
Reoxygenation led to a slight but not significant increase in ET-1 response relative to 
normoxia. 
These results show that ET-1 release from the coronary endothelium, as for ex- 
ample, induced by tissue hypoxia14 can give long-lasting signal transduction in the 
myocardial cells at a low level. During the hypoxic period the ET-1-evoked response 
is further decreased by a decline in responsiveness of the cells. ET-1-induced increases 
in intracellular free Ca2+ by stimulation of Na+/H+ exchange, opening of T-type chan- 
nels, and 1(1,4,5)P3-induced Ca2+ mobilization may contribute to development of 
Ca2+ overload, which is generally thought to be causally related to development of ir- 
reversible cell injury. 
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